Matching articles for "Evusheld"
Issue 1702 · May 13, 2024 Free
COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis

The FDA has issued an Emergency Use Authorization (EUA) for the long-acting investigational IV monoclonal antibody pemivibart ( Pemgarda – Invivyd) for pre-exposure prophylaxis of COVID-19 in persons ≥12…

Med Lett Drugs Ther. 2024 May 13; 66(1702):79-80 doi:10.58347/tml.2024.1702e
The FDA has issued an Emergency Use Authorization (EUA) for the long-acting investigational IV monoclonal antibody pemivibart ( Pemgarda – Invivyd) for pre-exposure prophylaxis of COVID-19 in persons ≥12 years old (weight ≥40 kg) who have moderate to severe immune compromise and are unlikely to respond adequately to COVID-19 vaccination (see Table 1). Pemgarda is the only drug that is currently authorized in the US for pre-exposure prophylaxis of COVID-19. Tixagevimab/cilgavimab (Evusheld) was previously available under an EUA for this indication, but it lacks activity against currently circulating SARS-CoV-2 variants.
Issue 1669 · February 6, 2023 Free
COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant (online only)

The FDA has warned that the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld – AstraZeneca) are unlikely to neutralize the XBB.1.5 Omicron variant of SARS-CoV-2.…

Med Lett Drugs Ther. 2023 Feb 6; 65(1669):e25 doi:10.58347/tml.2023.1669e
The FDA has warned that the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld – AstraZeneca) are unlikely to neutralize the XBB.1.5 Omicron variant of SARS-CoV-2. Evusheld is available under an Emergency Use Authorization (EUA) for IM pre-exposure prophylaxis of COVID-19 in persons ≥12 years old who weigh ≥40 kg and have either a history of a severe adverse reaction that prevents their vaccination against COVID-19 or moderate or severe immune compromise.
Issue 1656 · August 8, 2022 Free
COVID-19 Update: Dosing Interval for Tixagevimab/Cilgavimab (Evusheld) (online only)

The FDA has amended its Emergency Use Authorization (EUA) for the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab ( Evusheld – AstraZeneca) to recommend repeat dosing every 6…

Med Lett Drugs Ther. 2022 Aug 8; 64(1656):e122-3
The FDA has amended its Emergency Use Authorization (EUA) for the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab ( Evusheld – AstraZeneca) to recommend repeat dosing every 6 months in patients who require ongoing protection against COVID-19. Evusheld is authorized for IM pre-exposure prophylaxis of COVID-19 in persons ≥12 years old who weigh ≥40 kg and have either a history of a severe adverse reaction that prevents their vaccination against COVID-19 or moderate or severe immune compromise
Issue 1654 · July 11, 2022 Free
COVID-19 Update: Hypersensitivity Reactions with Tixagevimab/Cilgavimab (Evusheld)

The labeling for the investigational, long-acting, prophylactic anti-SARS-CoV-2 monoclonal antibodies tixagevimab and cilgavimab ( Evusheld ; available under an FDA Emergency Use Authorization) now includes…

Med Lett Drugs Ther. 2022 Jul 11; 64(1654):112
The labeling for the investigational, long-acting, prophylactic anti-SARS-CoV-2 monoclonal antibodies tixagevimab and cilgavimab ( Evusheld ; available under an FDA Emergency Use Authorization) now includes warnings about a risk of serious hypersensitivity reactions, including anaphylaxis, with use of the drugs, particularly in patients who have experienced a hypersensitivity reaction to a COVID-19 vaccine.
Issue 1646 · March 21, 2022 Free
COVID-19 Updates

The CDC has issued new guidance allowing for an interval of up to 8 weeks between the first and second primary doses of an mRNA COVID-19 vaccine in certain patients 12-64 years old.1 Product labeling currently…

Med Lett Drugs Ther. 2022 Mar 21; 64(1646):47-8
The CDC has issued new guidance allowing for an interval of up to 8 weeks between the first and second primary doses of an mRNA COVID-19 vaccine in certain patients 12-64 years old.1 Product labeling currently recommends a 3-week interval between the first two doses of the Pfizer/BioNTech mRNA vaccine (Comirnaty) and a 4-week interval between the first two doses of the Moderna mRNA vaccine (Spikevax) . The new guidance is based on data suggesting that a longer interval can decrease the risk of myocarditis and may improve vaccine efficacy.
Issue 1641 · January 10, 2022 Free
Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19

The FDA has issued an Emergency Use Authorization (EUA) for the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab ( Evusheld – AstraZeneca) to be administered concomitantly by IM…

Med Lett Drugs Ther. 2022 Jan 10; 64(1641):1-2
The FDA has issued an Emergency Use Authorization (EUA) for the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab ( Evusheld – AstraZeneca) to be administered concomitantly by IM injection for pre-exposure prophylaxis of COVID-19 in persons ≥12 years old who weigh ≥40 kg and have either a history of severe allergy that prevents their vaccination against COVID-19 or moderate or severe immune compromise (see Table 1). They are the first drugs to be authorized by the FDA for this indication. Two other pairs of antibodies, bamlanivimab plus etesevimab (Lilly) and casirivimab plus imdevimab (REGEN-COV), are authorized for post-exposure prophylaxis of COVID-19.